GSK says EMA validates cancer drug submission

GSK

1,334.00p

17:10 23/12/24

1.06%

14.00p

GSK said the European Medicines Agency had validated the its submission for a potential new indication of its treatment for a type of gynaecological cancer known as mismatch repair deficient primary advanced or recurrent endometrial cancer.

FTSE 100

8,102.72

17:14 23/12/24

n/a

FTSE 350

4,471.06

17:09 23/12/24

n/a

FTSE All-Share

4,428.73

16:44 23/12/24

n/a

Pharmaceuticals & Biotechnology

20,005.17

17:09 23/12/24

1.24%

244.05

The move comes after the first part of a phase 3 trial of its Jemperli (dostarlimab) treatment in combination with chemotherapy for adult patients.

As a result, the EMA's Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission regarding marketing authorisation for the potential new indication.

Reporting by Frank Prenesti for Sharecast.com